David Dible
David has over 35 years of experience in the healthcare, pharmaceutical and biotechnology sectors. He provides board-level strategic communications consultancy to clients in the UK and Europe. In recent years he has provided advice on a range of issues to mid-sized international companies including: Actelion (successful defence against hostile activist shareholder Elliott Advisors) ), Lonza (M&A), Zentiva (IPO, M&A) and Alere (acquisition of Axis-Shield), as well as to emerging biotechs, including: Algeta, ThromboGenics and Vectura (M&A, IPO and/or secondary financings, partnering deals, clinical results and regulatory filings). David has a clear understanding of how to successfully conduct financial communications on behalf of clients globally. He has been a rated pharma analyst in the UK, Europe and Japan. In addition to being a successful investment manager he has run cross-border investor relations and financial communications in-house for a number of international biotech and healthcare companies.